



(12) Translation of  
European patent specification

(11) NO/EP 3064579 B1

NORWAY

(19) NO  
(51) Int Cl.  
**C12N 9/50 (2006.01)**  
**A61K 38/48 (2006.01)**  
**A61P 35/00 (2006.01)**  
**C07K 19/00 (2006.01)**  
**C12N 15/57 (2006.01)**  
**C12N 15/62 (2006.01)**

**Norwegian Industrial Property Office**

---

(45) Translation Published 2020.12.28

(80) Date of The European Patent Office Publication of the Granted Patent 2020.09.30

(86) European Application Nr. 16163214.6

(86) European Filing Date 2009.11.02

(87) The European Application's Publication Date 2016.09.07

(30) Priority 2008.10.31, US, 110218 P

(84) Designated Contracting States: AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR

(62) Divided application EP2350273, 2009.11.02

(73) Proprietor AERase, Inc., 901 S. MoPac Expressway Barton Plaza One, Suite 250, Austin, TX 78746, USA

(72) Inventor Georgiou, George, 6405 Williams Ridge Way, Austin, TX 78731, USA  
Stone, Everett, 7004 Deborah Drive, Austin, TX 78752, USA

(74) Agent or Attorney PLOUGMANN VINGTOFT, Postboks 1003 Sentrum, 0104 OSLO, Norge

---

(54) Title **PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES OF ENGINEERED HUMAN ARGINASES**

(56) References Cited: Stone E. et al.: "Engineering Human Arginase I as a Novel Cancer Therapeutic Agent", , 18 January 2009 (2009-01-18), XP002675137, Retrieved from the Internet: URL:[http://aiche.confex.com/aiche/09icbe/p\\_reliminaryprogram/abstract\\_143378.htm](http://aiche.confex.com/aiche/09icbe/p_reliminaryprogram/abstract_143378.htm) [retrieved on 2012-02-29]

CARVAJAL N ET AL: "Consequences of mutations of metal ligands in human liver arginase I.", MOLECULAR BIOLOGY OF THE CELL, vol. 13, no. Supplement, November 2002 (2002-11), page 546A, XP009157032, & 42ND ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY; SAN FRANCISCO, CA, USA; DECEMBER 14-18, 2002 ISSN: 1059-1524

Nelson Carvajal ET AL: "Interaction of arginase with metal ions: studies of the enzyme from human liver and comparison with other arginases", Comparative Biochemistry and Physiology

pages 153-159, XP055413141, AMSTERDAM, NL ISSN: 1096-4959, DOI: 10.1016/0305-0491(95)00027-6

REHNER G ET AL: "EFFECT OF MANGANESE COBALT AND NICKEL ON THE ACTIVITY OF LIVER ARGINASE IN-VITRO AND IN-VIVO", MEDIZIN UND ERNAEHRUNG, vol. 11, no. 2, 1970, pages 32-35, XP009158520,

DAVID E ASH: "Structure and Function of Arginases", THE JOURNAL OF NUTRITION, AMERICAN SOCIETY FOR NUTRITION, US, vol. 134, no. 10, 1 October 2004 (2004-10-01), pages 2760S-2764S, XP008146967, ISSN: 0022-3166

CHENG P N M ET AL: "Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma", CANCER LETTERS, NEW YORK, NY, US, vol. 224, no. 1, 16 June 2005 (2005-06-16) , pages 67-80, XP004904542, ISSN: 0304-3835

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

**PATENTKRAV**

1. Variant av humant arginase I-protein hvori
  - i. den naturlige metallkofaktoren ( $Mn^{2+}$ ) erstattes med kobolt ( $Co^{2+}$ )
  - ii. varianten humant arginase I-protein omfatter en aminosyresekvens kodet av SEQ. ID NO: 1 bortsett fra at den har:  
minst én aminosyresubstitusjon i en posisjon valgt fra His101, Asp124, His126, Asp128, Asp232, Asp234, Asp181, Ser230 og Cys303; og mangler eventuelt N-terminal metionin;  
hvori proteinet utviser en  $k_{cat}/K_m$  som er større enn  $400 \text{ mM}^{-1}\text{s}^{-1}$  ved  $37^\circ \text{C}$  og pH 7,4.
2. Variant humant arginase I-protein ifølge krav 1, hvori aminosyresekvensen mangler et N-terminal metionin.
3. Variant humant arginase I-protein ifølge krav 1 eller krav 2, hvori proteinet er kovalent bundet til polyetylenglykol.
4. Fusjonsprotein omfattende et variant humant arginase I-protein ifølge et hvilket som helst av kravene 1 til 3 og et heterologt peptidsegment omfattende Fc-regionen til et immunglobulin eller en del derav.
5. Variant humant arginase I-protein ifølge et hvilket som helst av kravene 1 til 4 til anvendelse i terapi.
6. Farmasøytisk sammensetning omfattende et variant humant arginase I-protein ifølge et hvilket som helst av kravene 1 til 4.